It has recently been shown that there are highly significant associations for common single nucleotide polymorphisms (SNPs) near the CDKN2B-AS1 gene region at the 9p21 locus with primary open angle glaucoma (POAG), a leading cause of irreversible blindness. This gene region houses the CDKN2B/p15INK4B, CDKN2A/p16INK4A and p14ARF (rat equivalent, p19ARF) tumour suppressor genes and is adjacent to the S-methyl-5′-thioadenosine phosphorylase (MTAP) gene. In order to understand the ocular function of these genes and, therefore, how they may be involved in the pathogenesis of POAG, we studied the distribution patterns of each of their products within human and rat ocular tissues. MTAP mRNA was detected in the rat retina and optic nerve and its protein product was localised to the corneal epithelium, trabecular meshwork and retinal glial cells in both human and rat eyes. There was a very low level of p16INK4A mRNA present within the rat retina and slightly more in the optic nerve, although no protein product could be detected in either rat or human eyes with any of the antibodies tested. P19ARF mRNA was likewise only present at very low levels in rat retina and slightly higher levels in the optic nerve. However, no unambiguous evidence was found to indicate expression of specific P19ARF/p14ARF proteins in either rat or human eyes, respectively. In contrast, p15INK4B mRNA was detected in much higher amounts in both retina and optic nerve compared with the other genes under analysis. Moreover, p15INK4B protein was clearly localised to the retinal inner nuclear and ganglion cell layers and the corneal epithelium and trabecular meshwork in rat and human eyes. The presented data provide the basis for future studies that can explore the roles that these gene products may play in the pathogenesis of glaucoma and other models of optic nerve damage.
Citation: Chidlow G, Wood JPM, Sharma S, Dimasi DP, Burdon KP, Casson RJ, et al. (2013) Ocular Expression and Distribution of Products of the POAG-Associated Chromosome 9p21 Gene Region. PLoS ONE8(9): e75067. https://doi.org/10.1371/journal.pone.0075067
Editor: Balraj Mittal, Sanjay Gandhi Medical Institute, India
Received: February 22, 2013; Accepted: August 10, 2013; Published: September 19, 2013
Copyright: © 2013 Chidlow et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Support from the National Health and Medical Research Council (http://www.nhmrc.gov.au/) in terms of a project grant (number APP1031347) is gratefully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: One of the authors, Dr. Glyn Chidlow, is a PLOS ONE Editorial Board member. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
Glaucoma is a leading cause of irreversible blindness and manifests as an age-related, progressive optic neuropathy with a poorly understood pathogenesis and limited treatment options . It affects approximately 2.5% of the general population over 40 years of age, with the prevalence increasing exponentially thereafter , . The most common form of glaucoma is primary open-angle glaucoma (POAG), which has a poorly understood cause and pathogenesis but which makes up approximately 74% of all cases . This particular form of glaucoma is usually treated by lowering intraocular pressure (IOP). Although such a treatment regimen can delay progression of the disease in many cases, patients often present only after irreversible retinal damage has occurred. Therefore, further research is essential to address the underlying causes of POAG.
In recent years, researchers have attempted to elucidate pathological mechanisms involved in the etiology of POAG by identifying familial links that may indicate a genetic basis for this disease. The first gene to be identified as such was MYOC which encodes the myocilin protein in trabecular meshwork (TM) cells , . Indeed, MYOC mutations are now known to underlie 3–5% of POAG cases. Other genes identified in a similar manner to play potential roles in glaucoma pathogenesis are the OPTN , the NTF4  and the WDR36  genes.
A related analytical tool employed to aid elucidation of the pathogenesis of POAG has been the genome-wide association study (GWAS). This method determines the prevalence of single nucleotide polymorphisms (SNPs) at distinct genetic loci which are significantly associated with a particular disease: in this case, POAG. The first SNP location reproducibly identified using a GWAS approach was the CAV1/CAV2 locus on chromosome 7q34, which encodes the caveolin 1 and caveolin 2 proteins , . More recent studies identified significant genome-wide association with POAG at the rs4656461 SNP near the TMCO1 gene (encoding transmembrane and coiled-coil domain-containing protein 1; TMCO1) on chromosome 1q24 , , . Subsequent analysis of TMCO1 expression within the human eye showed that although having an unknown function, this protein localised to nuclear inclusions (nucleoli) in most tissue regions, including both the retina and trabecular meshwork, implying a role in cellular control .
The most significant region to be identified, by independent research groups, as having an association with POAG in different population samples is the CDKN2B-AS1 region on chromosome 9p21 , , , , , , , , , , , . The significance of this finding derives from the fact that SNPs which affect genetic expression in the region of CDKN2B-AS1 are known to be associated with a number of diseases such as coronary heart disease , , , types 1 and 2 diabetes , , , atherosclerosis  and different cancers (see reviews by Pasmant et al., 2011 and Cunnington et al., 2010 , ). CDKN2B-AS1 or ANRIL (anti-sense non-coding RNA at the INK4 locus) encodes an extended non-coding RNA spanning 19 exons which resides in the CDKN2B/p15INK4B-CDKN2A/p16INK4A-p14ARF tumor suppressor gene cluster  (see figure 1). This RNA gene is also adjacent to the MTAP gene, which encodes the protein S-methyl-5′-thioadenosine phosphorylase (MTAP) . The proteins p15INK4B and p16INK4A are involved in cellular proliferation and senescence by inhibiting cyclin-D binding at cell cycle-regulating cyclin-dependent kinases . Human p14ARF (rat homologue is p19ARF) is transcribed from an alternate reading frame of the p16INK4A locus in response to sustained mitogenic stimulation, and is involved with nucleolar regulation of ribosome biosynthesis, initiation of p53-dependent cell cycle arrest and apoptosis , . MTAP is involved with polyamine, methionine and adenine metabolism . Thus, SNPs causing altered expression of any of the genes derived from this region of the 9p chromosome may have serious pathological consequences.
Organisation of the CDKN2A/ARF, CDKN2B and CDKN2B-AS1 genes at the 9p21 locus and the neighbouring gene, MTAP. The boxes represent exons, numbers in boxes correspond to exon numbers, lines between boxes represent introns/intergenic regions, V-lines represent exon-splicing, arrows represent encoded transcript/protein and double-slash indicates large intergenic region. The two gene products, CDKN2A and ARF, encoded by the CDKN2A/ARF gene are respectively represented in red and light red. The SNP most significantly associated with open-angle glaucoma in the CDKN2B-AS1 gene is represented by an orange diamond. Note: the figure is not drawn to scale.
Since it is known that SNPs associated with the CDKN2B-AS1 gene region effectively comprise a major “hotspot” that relates to many diseases , , then the finding that this region is strongly and reproducibly associated with POAG is extremely significant. The present study therefore sought to investigate the ocular expression and localisation patterns of products from the CDKN2B-AS1 gene region. Detailed information on the previously unstudied ocular expression profiles of the gene products encoded by these loci, is likely to be of great importance in determining their role in glaucoma pathogenesis.
Materials and Methods
Adult Sprague-Dawley (SD) rats (8–10 weeks old) were obtained from The University of Adelaide and were housed according to the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, 2004, and the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research. The work was approved by the South Australia (SA) Pathology/Central Northern Health (CNH) Animal Ethics Committee. No actual experimental procedures were carried out on animals: when tissue was required, all tissues were procured by rapid killing of animals under terminal anaesthesia by trans-cardiac perfusion with 0.9% (w/v) NaCl solution to achieve exsanguination. In some cases, rat liver and brain cortex samples were also prepared (for Western immunoblot or reverse-transcription polymerisation chain reaction; RT-PCR). For some optic nerve analysis, pigmented inbred Dark Agouti (DA) rats (8–10 weeks old) were also analysed: samples from these animals were prepared in the same way as for the standard SD rats. For each antibody tested, and each analytical method used, at least 6 animals were assessed. Human ocular tissue for analysis was obtained from the Eye-Bank of South Australia, Flinders Medical Centre (Adelaide, Australia) following the guidelines of the Southern Adelaide Clinical Human Research Ethics Committee; all had been screened to make sure there was no underlying ocular disease and all were from Caucasian donors between the ages of 50 and 65. Tissue sections of malignant pleural mesothelioma and cervical adenocarcinoma, which served as positive controls in the present study, were sourced from positive control blocks provided by the Surgical Diagnostic facility of SA Pathology (Adelaide, Australia).
A review of the relevant literature revealed that each of the protein products to be analysed (MTAP, p14ARF [human tissue], p19ARF [rat tissue], p16INK4A, p15INK4B) have had their expression in various tissues determined by the use of a number of antibodies. It was therefore decided in the interests of accuracy and consistency to use a selection of the most frequently used antibodies for each protein under analysis, in order to determine the most reproducible expression/localisation data. Antibody data is summarised in Table 1.
Other un-related antibodies (eg. β-actin, Ret-P1 for rhodopsin, α-tubulin, FGF-2, vimentin, CD45, glutamine synthetase) were used as described previously , with appropriate dilutions recorded where employed.
Recombinant Proteins as Positive Controls
To test the specificity for each antibody under investigation, recombinant proteins for each of the species under test were obtained. These were to enable positive reactivity testing and pre-adsorption neutralisation for each relevant antibody. A human-specific protein/peptide for p14ARF was unable to be obtained, although a rodent-specific version (p19) was procured. p19ARF peptide was from Abcam (Cambridge, UK; #ab2659; 5 mg/ml) and p16INK4A, p15INK4B and MTAP proteins were obtained from Abnova (Walnut, CA, USA). The latter three products were obtained as GST-fusion products; hence these peptides had molecular masses that were 26 kD larger than reported values in each case (due to the additional mass of GST). Details: p15INK4B, human sequence with full length ORF (residues 1–138), #H00001030-P01, 0.04 µg/ml; p16INK4A, human sequence with full length ORF (residues 1–105), #H00001029-P01, 0.25 µg/ml; MTAP, human sequence with full length ORF (residues 1–283), #H00004507-P01, 0.09 µg/ml.
Tissue Processing and Immunohistochemistry
Whole eyes plus attached optic nerves that were subsequently used for immunohistochemistry were immersion-fixed in either 10% (w/v) neutral buffered formalin for 24–72 h until processing, or in Davidson’s solution (2 parts 37% formaldehyde, 3 parts 100% ethanol, 1 part glacial acetic acid and 3 parts water) for 24 h followed by 70% ethanol until processing. Davidson’s solution is the preferred fixative for whole eyes as it provides optimal tissue preservation without artefactual retinal detachment. Eyes were subsequently hand-processed according to the following schedule: 70% ethanol (30 min), 3×100% ethanol (30 min), 2×xylene (30 min), 50% xylene/50% wax (30 min) at 62°C, 2×wax (30 min) at 62°C. Globes were embedded in a sagital orientation and 4 µm sections were cut using a rotary microtome.
Immunohistochemistry of transverse ocular sections was performed as previously described , . Briefly, tissue sections were deparaffinised and endogenous peroxidase activity was blocked with H2O2. Antigen retrieval was performed by microwaving sections in 1 mM EDTA (pH 8.0) and non-specific labelling blocked with PBS containing 3% normal horse serum (PBS-HS). Sections were incubated overnight at room temperature in primary antibody (in PBS-HS), followed by consecutive incubations with biotinylated secondary antibody (Vector, Burlingame, CA) and streptavidin-peroxidase conjugate (Pierce, Rockford, IL). Color development was achieved using NovaRed substrate kit (Vector, Burlingame, CA) for 3 min. Sections were counterstained with hematoxylin, dehydrated, cleared in histolene and mounted in DPX. In order to evaluate specificity of antibody labelling, adjacent sections were incubated with the appropriate isotype control for monoclonal antibodies, or normal rabbit/goat serum for polyclonal rabbit/goat antibodies. In addition, Western blotting was performed for the majority of the antibodies used.
For antibody-antigen neutralisation studies, antibodies were pre-adsorbed with or without a ten-fold excess of the appropriate recombinant protein in PBS-HS for three hours on a rotary shaker at room temperature before being applied to sections in a standard manner.
Dissected tissue was sonicated in homogenisation buffer (20 mM Tris-HCl, pH 7.4, 25°C; with 2 mM EDTA, 0.5 mM EGTA, 1 mM dithiothreitol, 50 µg/ml leupeptin, 50 µg/ml pepstatin A, 50 µg/ml aprotinin and 0.1 mM phenylmethylsulphonyl fluoride). An equal volume of sample buffer (62.5 mM Tris-HCl, pH 7.4, containing 4% SDS, 10% glycerol, 10% β-mercaptoethanol and 0.002% bromophenol blue) was subsequently added and samples were boiled for 5 minutes. In order to ensure even running of samples on gels, protein concentrations for each tissue extract were equalized according to the method of Bradford .
Electrophoresis was performed using a Mini-PROTEAN® TGX™ precast gel system (Bio-Rad Laboratories Pty Ltd, Gladesville, New South Wales, Australia). Denaturing 12% (w/v) polyacrylamide gels were employed for protein separation, as described previously . Separated proteins were transferred to polyvinylidine fluoride membranes (PVDF; Bio-Rad Laboratories Pty Ltd) for labelling. Membranes were incubated with appropriate primary antibody overnight, and actual labelling of immunoblots carried out using a two-step detection procedure: first, appropriate biotinylated secondary antibodies were applied (Vector Laboratories; 1∶500; 30 minutes) and subsequently streptavidin-peroxidase conjugates (Pierce, Rockford, Il, USA). Blocking of membranes was carried out in a solution of tris-buffered saline (TBS) containing 0.1% (v/v) Tween-20 and 5% (w/v) non-fat dried skimmed milk (TBS-TM). Positive antibody labelling was detected as described previously  and quantification of detected proteins was achieved, where appropriate, using the program, Adobe PhotoShop CS2. Detection of β-actin was assessed where suitable as a positive gel-loading control.
For Western immunoblot testing of specificity of each antibody to recognise the appropriate antigen, recombinant proteins were resolved on 12% SDS-PAGE gels after loading at either 100 ng or 10 ng per lane before being detected as described above.
Real time PCR studies were carried out essentially as described previously , . In brief, the required tissues were dissected, total RNA was isolated and first strand cDNA was synthesised from DNase-treated RNA samples. Real-time PCR reactions were carried out in 96-well optical reaction plates using the cDNA equivalent of 20 ng total RNA for each sample in a total volume of 25 µl containing 1×SYBR Green PCR master mix (BioRad), forward and reverse primers. Thermal cycling conditions were 95°C for 3 min and 40 cycles of amplification comprising 95°C for 12 s, appropriate annealing temperature for 30 s and 72°C for 30 s. Primers employed for the study are outlined in Table 2. To allow a comparison to be made between the levels of expression of test mRNAs in the different tissues, results were semi-quantified using the Relative Expression Software Tool (REST©). Threshold cycles were calculated using IQ5 icycler Software (Bio-Rad), all values were normalised using the endogenous reference gene, cyclophilin, and results expressed as mean ± SEM.
This murine cell-line  comprises retina-derived cells which can be differentiated into neurons . They were cultivated exactly as described previously . Their use in the present study was to provide a positive control preparation for identification of P19ARF.
Immunocytochemical Analysis of Cultures
Cells on coverslips were fixed with neutral-buffered formalin containing 1% methanol for 15 minutes and then washed in phosphate buffered saline (PBS; 137 mM NaCl, 5.4 mM KCl, 1.28 mM NaH2PO4, 7 mM Na2HPO4; pH 7.4). Cells were permeabilised with PBS containing 0.1% (v/v) Triton X-100 (PBS-T), followed by further washing in PBS and then blocking in PBS-HS. Test antisera (see Table 1), diluted in PBS-HS, were applied overnight at room temperature and labelling completed with consecutive incubations in appropriate biotinylated secondary antibodies (Vector Laboratories, Abacus ALS, Brisbane, Australia; 1∶250 in PBS-HS; 30 minutes) and streptavidin-AlexaFluor 488 or streptavidin-AlexaFluor 594 (Molecular Probes, Invitrogen, Mulgrave, Victoria, Australia; 1∶500 in PBS-HS; 1 hour). Cells on coverslips were mounted using anti-fade mounting medium (DAKO, Botany, New South Wales, Australia) and examined under a confocal fluorescence microscope.
Table 3 shows the expression level of MTAP mRNA, relative to the housekeeping gene cyclophilin, in four rat tissues (brain cortex, liver, optic nerve and retina) using two distinct sets of primers to ensure reproducibility. The first point to note is that there was a good agreement between the two primer sets. Regarding abundance, there was a broadly similar level of MTAP mRNA across the different tissues. The MTAP transcript is present at approximately 0.3% and 1% of the level of glyceraldehyde-3-phosphate dehydrogenase and cyclophilin, respectively, in retina and optic nerve, with somewhat higher and lower levels present in the liver and brain samples, respectively.
To investigate ocular expression of MTAP protein, three distinct commercially available antibodies (CST, Santa-Cruz, Proteintech) were obtained. Initially, each antibody was tested for reactivity against recombinant human MTAP (rMTAP), which, when conjugated to GST, has a predicted molecular mass of 57 kD. All three antibodies were able to detect 100 ng rMTAP (figure 2A); the Proteintech and Santa-Cruz antibodies also detected 10 ng rMTAP (Fig. S1A). When incubated with rat tissue extracts, all three antibodies were able to distinguish proteins at the predicted molecular mass (31 kD) in liver and retina, but only the Proteintech and Santa-Cruz preparations detected a signal in the optic nerve (Fig. 2, S1B).
(A) Evaluation of the MTAP antibody by Western immunoblotting using GST-tagged, full length, recombinant, human MTAP protein (rMTAP). Molecular weight markers were used to determine size of detected gel products (A; lane M). Lane 1, 100 ng rMTAP; Lane 2, 10 ng rMTAP; Lane 3, 1 ng rMTAP; Lane 4, 100 pg rMTAP. A single band of the expected molecular weight (including GST-tag) is apparent; results plotted on bar graph to show quantitative distribution. (B) Rat brain cortex (lane 1), liver (lane 2), optic nerve (lane 3) and retina (lane 4) samples probed for MTAP. A protein is detected at the correct molecular mass for MTAP in the liver, optic nerve and retinal samples. Labelling for β-actin (housekeeping gene) and α-tubulin (neuronal tissue marker) are also shown; results plotted on bar graph to show quantitative distribution. (C) Evaluation of MTAP expression in retina (lanes 1–3) and optic nerve (lanes 4–6) samples obtained from three different rats. MTAP protein is detectable in all samples; results plotted on bar graph to show quantitative distribution. (D–G) Evaluation of MTAP antibodies in malignant pleural mesothelioma. In formalin-fixed, paraffin-embedded tissue sections, many inflammatory cells, as identified by immunoreactivity for CD45 (leukocyte common antigen; D), display positive labelling for MTAP using the Proteintech antibody (PT Ab; E). Some fibroblastic cells, negative for CD45 (F), also display positive labelling for MTAP using the PT antibody (G, arrow). Scale bar = 30 µm.
Previous work has used immunohistochemistry to reliably detect MTAP expression in formalin-fixed, paraffin-embedded malignant pleural mesothelioma . As a consequence, such tissue served as a positive control in the present study, both in terms of analyzing the sensitivity of the various primary antibodies used and in verifying the effectiveness of our immunohistochemistry methodology. The MTAP antibody from Proteintech correctly identified inflammatory cells and fibroblasts with a good signal-to background ratio (Fig. 2D–G). This finding, coupled with the positive results obtained from the Western blotting experiments, attested to its reliability in detecting MTAP. In contrast, the antibodies from CST and Santa-Cruz yielded weaker patterns of immunolabelling than that obtained with the Proteintech antibody (Fig. S2), even at low antibody dilutions. This result was replicated when the antibodies were tested on ocular sections, hence only data obtained using the Proteintech antibody are shown hereafter.
Ocular expression of MTAP.
In human eye sections, MTAP was associated with cells in the corneal epithelium, trabecular meshwork and retina (Fig. 3A–C). Further investigation of the localisation within the retina, which was achieved by double-labelling immunofluorescence with glutamine synthetase, revealed MTAP immunoreactivity to be principally associated with astrocytes and Müller cells (Fig. 3D–F). An association with neuronal components cannot be ruled out, however. MTAP displayed a broadly similar pattern of immunolabelling in rat ocular sections to that observed in humans (Fig. 3-L). Of note, however, in the retina MTAP appeared to be restricted to astrocytes. Unlike the human eye, no labelling of Müller cell somas or processes was apparent.
In formalin-fixed, paraffin-embedded human eyes, positive labelling for MTAP is discernible in cells located in the corneal epithelium (A) and trabecular meshwork/Schlemm’s canal (B). In the retina, MTAP labelling is associated with astrocytes (arrow) and Müller cell somas (inset) and processes (C). Verification of MTAP expression by Müller cells was obtained by double-labelling immunofluorescence of MTAP (red) with the Müller cell marker glutamine synthetase (Glut Syn; green; D–F). In formalin-fixed, paraffin-embedded rat eyes positive labelling for MTAP is similarly detectable in corneal epithelial cells (G). Interestingly, in eyes fixed in Davidson’s solution, which affords superior morphological preservation, MTAP expression is strongly detected within the membranes of corneal epithelial cells (H). In the retina (I), ONH (J) and ON (K), MTAP labelling is principally localised to astrocytes. The pattern of immunoreactivity displays marked similarity to GFAP, as illustrated in (L). Scale bar: A, D–L = 15 µm; B, C = 30 µm. TM, trabecular meshwork; SC, Schlemm’s canal; GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; ONH, optic nerve head.
Analysis of retina and optic nerve samples from three rats revealed MTAP expression in all samples (Fig. 2C). Densitometry indicated that although there was a tendency for there to be a higher expressed level of the MTAP protein in the retina versus the optic nerve, this was not statistically significant (Fig. 2C).
P16INK4A and p19ARF are both products of the rat CDKN2A gene, each having a unique first exon, but sharing exons 2 and 3. In preliminary results, contained within our previous study , we made use of primers that amplified a cDNA region common to both mRNAs. Herein, we have again used these primers for comparative purposes, but also primers specific to each transcript. Table 4 shows the expression level of p16INK4A mRNA, relative to the housekeeping gene cyclophilin, in rat brain cortex, liver, optic nerve and retina. The common primers detected a very low level of expression of p16INK4A/p19ARF in the brain, retina and liver, but a greater amount within optic nerve samples. Using the p16INK4A-specific primers, a very low level of expression was measured in all four tissues, which, in the retina and optic nerve, approximated to 0.001% and 0.006%, respectively, of the level of cyclophilin.
For dissemination of expression levels of the p16INK4A protein in ocular tissues, four antibodies (Santa-Cruz, Proteintech, Sigma and Abnova) were investigated (Figs. S3, S4; see also Fig. 4). Full length GST-tagged recombinant p16INK4A protein was initially used as a positive control to determine antibody reactivity (Fig. S3A). The Proteintech, Sigma and Santa-Cruz (see also Fig. 4A) antibodies detected the recombinant protein at the correct molecular mass; the Abnova antibody did not recognise any protein signal. None of the antibodies reacted against recombinant p15INK4B protein (data not shown). Subsequent analysis of the antibodies in rat brain, liver, optic nerve and retina determined that none of the four tissues under investigation expressed measureable amounts of p16INK4A protein (Fig. S3B; see also Fig. 4B). Overexpression of p16INK4A protein is consistently encountered in cervical dysplasias, neoplasias or carcinomas of squamous and glandular cell/tissue types that are associated with high-risk human papillomavirus infection. Indeed, immunohistochemistry for p16INK4A is currently the subject of much attention regarding its suitability as a biomarker for cervical cancer screening , . As such, formalin-fixed, paraffin-embedded tissue sections from abnormal cervical tissue represented the ideal positive control for p16INK4A immunohistochemistry in the current study (Fig. S4). The antibodies from Santa-Cruz (see also Fig. 4D, E), Proteintech, and, to a somewhat lesser extent, Sigma identified p16INK4A-overexpressing glandular and epithelial cells with good signal-to background ratios. The p16INK4A antibody from Abnova less reliably demarcated abnormal tissue and elicited robust nuclear labelling of cells in surrounding tissue. The combined data raise serious questions about the specificity of the Abnova antibody, but indicate that data obtained from the other antibodies are valid.
(A) Evaluation of the specificity of the p16INK4A antibody, sc-1661, by Western blotting, using GST-tagged, full length, recombinant, human p16INK4A protein (rp16INK4A). Molecular weight markers were used to determine size of detected gel products (A; lane M). Lane 1, 100 ng of rp16INK4A; Lane 2, 10 ng rp16INK4A. A single band of the expected molecular weight (including GST-tag) is apparent. (B) Rat brain cortex (lane 1), liver (lane 2), optic nerve (lane 3) and retina (lane 4) samples probed for p16INK4A protein, using sc-1661. None of the four tissues under investigation unambiguously express p16INK4A protein. Labelling for β-actin (house-keeping gene product) is also shown. (C) The antibody was further tested against retina (lanes 1–3) and optic nerve (lanes 4–6) samples obtained from three different rats. The presence of p16INK4A protein is not detectable in any sample. (D, E) In formalin-fixed, paraffin-embedded tissue sections of cervical adenocarcinoma, incubation with sc-1661, identifies so-called ‘block’ or ‘diffuse’ immunolabelling of ductal (D) and epithelial (E) tissue with a high signal-to-background, as compared to adjacent tissue (arrow). Scale bar = 30 µm.
Ocular expression of p16INK4A.
In human eye sections, incubated identically to and simultaneously with cervical tissue sections, no specific p16INK4A immunolabelling was observed in the cornea, drainage angle, retina or optic nerve (Fig. 5A, B, C; see also Fig. S5); note the presence of pigment and not positive immunolabelling in the TM/Schlemm’s Canal images (Fig. 5B). More concentrated dilutions simply resulted in generic, non-specific staining (data not shown). Similarly, in rat ocular sections, no unambiguous evidence was found for p16INK4A protein expression in the cornea, retina or optic nerve (Fig. 5D, E, F; see also Fig. S6). In agreement with these findings, Western immunoblotting analysis of retina and optic nerve from three rats revealed no expression of p16INK4A in any sample (Fig. 4C; see also Fig. S3C).
In formalin-fixed, paraffin-embedded human eyes, no positive labelling for p16INK4A is discernible in the corneal epithelium (A), trabecular meshwork (TM)/Schlemm’s canal (SC) (B), or retina (C). In formalin-fixed, paraffin-embedded rat eyes, no positive labelling for p16INK4A is discernible in the corneal epithelium (D), retina (E) or optic nerve (F). Scale bar: A, B, D, F = 15 µm; C, E = 30 µm. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer.
P14ARF, the human homologue of p19ARF, has been shown to be localized mainly in the cellular nucleolus; it is also present in the nucleoplasm of cells expressing the protein . Characteristically, induction of p14ARF occurs in response to inappropriate hyperproliferative signals, such as in cancerous tissues. Alongside p16INK4A, expression of p14ARF has consistently been detected in abnormal cervical tissue , ; thus, we again used formalin-fixed, paraffin-embedded tissue sections from cervical lesions as a positive control for p14ARF immunohistochemistry. Both antibodies tested (Sigma and CST) identified p14ARF expression in nuclear inclusions within epithelial cells in abnomal cervical tissue, with the antibody from Sigma (Fig. 6A) displaying a better signal-to background ratio than the antibody from CST (Fig. S7A).
In formalin-fixed, paraffin-embedded sections of cervical intraepithelial neoplasia, p14ARF expression is identified, as expected, within nuclear inclusions (A). In formalin-fixed, paraffin-embedded human eyes, no positive labelling for p14ARF is discernible in the corneal epithelium (B), trabecular meshwork (TM)/Schlemm’s canal (SC) (C), retina (D), unmyelinated optic nerve (E), or myelinated optic nerve (F). Scale bar = 15 µm. GCL, ganglion cell layer; INL, inner nuclear layer.
Table 4 shows the expression level of p19ARF mRNA, relative to the housekeeping gene cyclophilin, in rat brain, liver, optic nerve and retina. As noted above, the common primers detected a very low level of expression of p16INK4A/p19ARF in the brain, retina and liver, but a greater amount within optic nerve samples. Using the p19ARF-specific primers, it was confirmed that the levels of transcript in the brain, liver and retina were indeed low (approximately 0.003–0.007% of the level of cyclophilin), and, that the greater amount in the optic nerve (approximately 0.2% of the level of cyclophilin) represented p19ARF rather than p16INK4A.
Antibody validation and ocular expression.
Expression of p19ARF protein in rat ocular tissues was examined using two distinct, commercially-available antibodies (Upstate, Santa-Cruz). Initially, to visualise positive immunolabelling for P19ARF, transformed, retina-derived, undifferentiated, rodent RGC-5 cells were grown to confluence and stained with both antibodies. The rationale for this test is that previous work has demonstrated p19ARF localization in the nucleolus of immortalised cells . The Santa-Cruz antibody appeared to label only some cytoplasmic granules (Fig. 7A, B, C), but the Upstate antibody clearly labelled nuclear inclusions (Fig. 7D, E, F). Since the immunocytochemical labelling in RGC-5 cells with the Upstate antibody resembled that reported previously for other immortalised cells , we believe this to be specific labelling and therefore the most applicable antibody for future studies.
(A–C) Use of the Santa Cruz antibody (A), shown in relation to nuclear DAPI counterstaining (B, C), reveals little P19ARF protein labeling except for some cytoplasmic granules (arrowheads). There is no obvious nuclear labeling. (D–F) Use of the p19ARF antibody from Upstate, however, denotes clear nuclear labeling within cells. The positive labeling appears to be present in nucleolar-like structures within cell nuclei (as denoted by DAPI-positive staining; arrows). This labeling is present in approximately 75% of cells. Scale bar = 10 µm.
To further verify the specificity of the Upstate and Santa-Cruz antibodies, both preparations were tested against recombinant rat p19ARF by Western blotting. The Upstate antibody clearly detected 100 ng and 10 ng recombinant p19ARF, but the Santa-Cruz antibody was unable to distinguish any signal (Fig. 8A). When analyzing rat tissue samples, however, the Upstate antibody failed to detect any proteins at the correct molecular mass (19 kD). Moreover, in brain cortex and optic nerve samples a protein with a mass of 48 kD was detected, and in liver and retina samples a protein with the mass of 35 kD was weakly distinguished (Fig. 8B). This was confirmed when 3 independent retina and optic nerve samples were analysed (Fig. 8C). From these results, it appears likely that the Upstate antibody cross-reacts with other proteins. Surprisingly, since it did not cross-react with the recombinant rat p19ARF, the Santa-Cruz antibody detected a 19 kD protein in optic nerve but not retina, brain cortex or liver samples (Figs. 8B, C).
(A) Evaluation of two p19ARF antibodies, from Upstate and Santa-Cruz (sc), by Western immunoblotting using full length, recombinant rat p19ARF protein (r P19ARF). For each antibody tested, molecular weight markers were used to determine size of detected gel products (A, C; lane M). Lane 1, 100 ng of r P19ARF; Lane 2, 10 ng rP19ARF. Single bands of the correct molecular mass are detectable by the Upstate antibody, but not by the Santa Cruz antibody. (B) Rat brain cortex (lane 1), liver (lane 2), optic nerve (lane 3) and retina (lane 4) samples probed for p19ARF protein with the Upstate and sc antibodies. The Upstate antibody does not recognize any proteins at the correct molecular mass, but the sc antibody recognises a 19 kD protein in the optic nerve sample. Labelling for β-actin (house-keeping gene product) is also shown. (C) Further testing of both antibodies against retina (lanes 1–3) and optic nerve (lanes 4–6) samples obtained from three different rats reveals that the Upstate antibody fails to detect a band at 19 kD in any sample, but detects a protein of approximately 38 kD in the retinal, and a protein of 48 kD in the optic nerve, samples. The sc antibody recognises a 19 kD protein in each optic nerve sample but not in the retinal samples. (D) Representative images of p19ARF immunolabelling using the Upstate p19ARF antibody in the rat retina and optic nerve. No nuclear staining is detectable in cells of the retina or optic nerve; however, robust labelling of axons in the myelinated, but not unmyelinated, optic nerve is apparent. This is most clearly shown in the image taken of the optic nerve head (ONH). Scale bar = 30 µm. GCL, ganglion cell layer; INL, inner nuclear layer.
In rat ocular sections, no evidence was found for nuclear p19ARF protein expression in the anterior segment (data not shown), retina (Fig. 8D) or optic nerve (Fig. 8D) when using the Upstate antibody. Interestingly, sections through the rat optic nerve head demonstrated a cross-reaction of the antibody with the myelinated portion of the optic nerve (Fig. 8D). This quite likely accounts for the non-specific band at 48kD observed in Western blots. As regards the Santa-Cruz antibody, no nuclear p19ARF protein expression was observed in the anterior segment, retina or optic nerve (data not shown).
The overall results for p19ARF suggest that the protein is not present at detectable levels in rat ocular tissues; however, the profile of neither antibody is totally convincing and some doubt remains.
Table 5 shows the expression level of p15INK4B mRNA, relative to the housekeeping gene cyclophilin, in rat brain, liver, optic nerve and retina. The p15INK4B transcript is present in considerably higher amounts in the optic nerve than in the retina (approximately 1.8% and 0.02% of the level of cyclophilin, respectively). Of interest is the fact that in both tissues expression was markedly higher than for p16INK4A. The levels of p15INK4B mRNA in the brain and liver were broadly similar to that measured in the retinal samples.
To determine expression of p15INK4B in rat ocular tissues, four distinct, commercially available antibodies (CST; Neomarkers; Abcam; Santa-Cruz) were employed. Initially, each antibody was tested against recombinant rat p15INK4B by Western blotting. Next, each antibody was tested against a variety of rat tissues by Western blotting. For the purposes of immunohistochemistry, antibodies were validated using formalin-fixed, paraffin-embedded tissue sections from abnormal cervical tissue and normal skin, since p15INK4B positive immunolabelling has previously been detected in cervical intraepithelial neoplastic lesions  and in cutaneous squamous cells .
The p15INK4B antibody from CST was able to detect the correct mass protein (GST-p15INK4B; 41 kD) when present at 100 pg-100 ng (Fig. 9A), but importantly did not cross-react with recombinant GST-p16INK4A (Fig. 9B). When tested against a variety of rat tissues by Western blotting, the CST antibody correctly recognised 15 kD products: in particular, positive reactivity was detected in liver (as defined previously ), retina and optic nerve (Fig. 9C). The specificity of the CST antibody was confirmed in additional retina and optic nerve samples (Fig. 9D), where no significant differences were found in expression levels. In tissue sections from abnormal cervical tissue (Fig. 10A) and normal skin (Fig. 10B), the CST antibody yielded patterns of immunolabelling in agreement with those previously described , . These results attest to the validity of the CST antibody for recognition of the p15INK4B protein. In contrast, the p15INK4B antibodies from Neomarkers, Abcam and Santa-Cruz produced unsatisfactory results (see Figs. S8, S9).
(A, B) Validation of p15INK4B antibody specificity by Western blotting using GST-tagged, full length, recombinant human p15INK4B (rp15INK4B) and p16INK4A (rp16INK4A) proteins. M, molecular weight markers. (A) Reactivity of antibody to rp15INK4B, where lane 1, 100ng of rp15INK4B; Lane 2, 10 ng rp15INK4B; Lane 3, 1 ng rp15INK4B P; Lane 4, 100 pg rp15INK4B. Single bands of the expected molecular weights (for protein incorporating GST-tag) are apparent. (B) Reactivity of antibody to rp16INK4A in order to determine any non-specific binding to the highly related protein p16INK4A, where lane 1, 100 ng of rp16INK4A; Lane 2, 10 ng rp16INK4A; Lane 3, 1 ng rp16INK4A; Lane 4, 100 pg rp16INK4A. (C) Rat brain cortex (lane 1), liver (lane 2), optic nerve (lane 3) and retina (lane 4) samples probed for rp15INK4B. A 15 kD protein is detectable in all tissue samples; results plotted on bar graph to show quantitative distribution. (D) Expression of p15INK4B in retinal (lanes 1–3) and optic nerve (lanes 4–6) samples. Labelling for β-actin (house-keeping gene product) is also shown; results for p15INK4B plotted on bar graph to show quantitiative distribution, relative to actin levels.
In formalin-fixed, paraffin-embedded tissue sections, weak, diffuse p15INK4B immunolabelling of the cervical intraepithelial neoplastic lesion (red asterisk) and robust labelling of a subset of inflammatory cells in the underlying stroma (arrow) is observed (A). In skin sections, p15INK4B immunoreactivity is associated with cutaneous squamous cells (B, arrows). In formalin-fixed, paraffin-embedded human eyes, positive labelling for P15INK4B is discernible in the nuclei of cells located in the corneal epithelium (C) and trabecular meshwork/Schlemm’s canal (D). In the retina, P15INK4B labelling is associated with the nuclei of cells within the GCL and INL (arrows; E, F). Scale bar: C, F = 15 µm; A, D, E = 30 µm; B = 60 µm. GCL, ganglion cell layer; INL, inner nuclear layer.
Ocular expression of p15INK4B.
In human eye sections, p15INK4B immunolabelling, as identified by use of the CST antibody, was associated with the nuclei of cells located in the corneal epithelium, trabecular meshwork and inner retina (Fig. 10C, D, E, F). In rat eye sections, p15INK4B immunolabelling was associated with nuclei in the ganglion cell and inner nuclear layers, but not in the outer nuclear layer (Fig. 11A). Preadsorption with recombinant p15INK4B protein reduced the intensity of labelling (Fig. 11B). More detailed scrutiny of the pattern of labelling in the retina revealed that it encompassed neurons but not Müller cells (Fig. 11C, D, E, F). In the optic nerve, p15INK4B immunolabelling was associated with the nuclei of glial columns (Fig. 11 G, H), particularly in the myelinated portion of the nerve.
(A) P15INK4B immunoreactivity is associated with nuclei within the GCL and INL (arrows), the intensity of which is substantially reduced after preadsorption with recombinant P15INK4B protein (B). Greater magnification images of retinas labelled with the CST antibody (C, E) reveal a pattern of labelling in the INL that encompasses neurons, but not Müller cells. For comparative purposes, the distribution of Müller cells is revealed in adjacent sections using an antibody directed against FGF-2 (D, F). In the optic nerve, labelling is observed within the nuclei of a subset of glial cells. Labelling is stronger in the myelinated portion of the nerve than in the unmyelinated ONH (black arrow indicates myelination transition zone). This effect is more pronounced in the Dark-Agouti (DA; H) strain of rat than the Sprague-Dawley strain (SD; G). Scale bar: A, B, G, H = 30 µm; C, D = 15 µm; E, F = 6 µm. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; FGF-2, fibroblast growth factor-2; ONH, optic nerve head.
In light of previous work defining the importance of gene products from the 9p21 locus in diseases such as coronary heart disease , , , diabetes , , atherosclerosis  and cancer , , the systematically validated discovery that SNPs from this region are also associated with POAG is of great significance , , , , , , , , , , , . The logical first step in disseminating the role that such gene products might play in POAG is an investigation into their expression and localization within the normal eye; such was the purpose of the current study. In undertaking this project, we concentrated on both human and rat ocular tissues. Rodent models of glaucoma are increasingly used to investigate the pathogenesis of retinal ganglion cell loss; thus, delineation of the expression patterns in both species permits a better understanding of the commonality between humans and rats and the relevance of conducting basic research.
Owing to the absence of suitable tissue from human eyes for analysis by Western blotting and RT-PCR, these latter techniques were restricted to the rat. This situation inevitably resulted in the main focus of the current study being on visualisation of 9p21 gene products by immunohistochemistry. This is not necessarily a straightforward task, despite the proliferation of commercially available antibodies, since biologically meaningful immunohistochemical data can only be obtained if the antibodies in question are meticulously validated using the methodologies employed by the researchers. Disturbingly, commercial antibodies often fail rudimentary tests of specificity , which, when combined with inadequate controls, leads to publication of erroneous results. The interrelated topics of antibody specificity and appropriate controls for use with immunohistochemistry have been covered in numerous reviews and editorials in recent years , , , . A number of immunohistochemistry controls can be employed, of which some of the more useful are as follows: (1) Western blot data showing both that the primary antibody can bind specifically to a correctly sized antigen and that such a band is observed in tissues displaying a positive immunohistochemical signal; (2) lack of signal in tissue from a knockout animal; (3) comparison of results from separate antibodies raised against different epitopes of the protein; (4) lack of signal in tissue with a known minimal level of expression of the molecule; (5) presence of cell-type specific labelling at high signal-to-background in tissue with known expression of the molecule; (6) correlation of protein expression with mRNA expression, for example by in situ hybridization or RT-PCR; (7) absence of signal when the primary antibody is preincubated with an excess of the antigen prior to use (preadsorption test). With the exception of the relevant knockout rats, which we were unable to obtain for this investigation, we have made use of all of these controls.
MTAP, an enzyme that plays an essential role in the salvage of cellular adenine and methionine following biosynthesis of polyamines, has been shown to be present in all normal mammalian tissues analysed with particularly high levels of activity described in the liver and lung , . Despite the growing interest in the role of MTAP, the cellular distribution of the protein in normal CNS tissue, and the eye in particular, has received negligible attention. Our results show that the levels of MTAP mRNA expression in the normal rat retina and optic nerve are comparable, each equating to about 0.3% and 1%, respectively, of the levels of the housekeeping genes glyceraldehyde 3-phosphate dehydrogenase and cyclophilin. The MTAP transcript, whilst not abundant, is expressed at a considerably higher level in the retina than the transcripts encoding p16INK4A, p15INK4B and p19ARF. As regards the protein, three commercially available antibodies were tested. Although each of the antibodies detected recombinant MTAP and were able to distinguish proteins at the predicted molecular mass in liver and retina samples using Western blotting, the polyclonal antibody from Proteintech proved best suited to detection of the protein in tissue sections. This antibody has previously been validated for detection of MTAP in malignant pleural mesothelioma , gastro-intestinal tumors ,  and chordoma  providing further evidence of its specificity. In the anterior segment of the human eye, positive immunolabelling was evident in both the corneal epithelium and trabecular meshwork, while in the retina, MTAP immunoreactivity was principally associated with astrocytes and Müller cells. In the rat retina, MTAP appeared to be associated with astrocytes but not Müller cells. It is possible that neuronal cells in the human and rat retina also express MTAP, but the protein abundance is below the detection limits of the immunohistochemical assay. Overall, the immunohistochemistry, Western blotting and real-time RT-PCR methodologies provided unambiguous results that correlated satisfactorily. Further studies should investigate whether MTAP expression in the trabecular meshwork and in glial cells of the retina and optic nerve is important in the pathogenesis of POAG.
P16INK4A is a principle member of the INK4 family of proteins, which also includes p15INK4B, p18INK4C and p19INK4D, and whose major function is to inhibit cyclin-dependent kinases (CDKs) and therefore exert control on the cell cycle (see review by Romagosa et al. ). P16Ink4A itself contributes to regulation of the cell cycle by binding to CDK4 and CDK6. In the absence or malfunctioning of p16Ink4A, these enzymes associate with cyclin-D and phosphorylate the retinoblastoma protein, ultimately activating transcription factors of the E2F family and promoting G1/S transition. Aberrant functioning of p16Ink4A can, therefore, have profound pathological influences derived from erroneous regulation of the cell cycle and/or entry of the cell into apoptosis . It is of no surprise, therefore, to find that alterations in physiological expression levels of p16Ink4A are associated with many types of human disease as well as with aging and senescence .
Preliminary data, included within our previous study , indicated high expression of p16INK4A in rat retina. This conclusion was based on immunohistochemical staining of tissue sections with antibody clone 2D9A12 (Abnova), which yielded high signal-to-background nuclear labelling in virtually all retinal cells. We were, therefore, surprised to discover that the rat retinal samples analysed in the present study had minimal expression of p16INK4A mRNA: the transcript level approximated to 0.001% to 0.008% of the level of the housekeeping cyclophilin, depending on the primer set used in the real-time PCR assay. The low level of p16INK4A mRNA in the retina agrees with previous research, which has shown that p16INK4A mRNA is not expressed at detectable levels in adult human ,  or rodent , ,  CNS. Although various studies have documented that p16INK4A is a relatively stable protein, the mismatch between mRNA and immunohistochemistry clearly needed addressing. To test the validity of clone 2D9A12, we performed Western blotting and immunohistochemistry using three further p16INK4A antibodies that are all reactive in rat and human tissue. Furthermore, we made use of arguably the definitive positive control tissue for expression of p16INK4A, namely abnormal cervical tissue. The diagnostic value of p16INK4A overexpression has been proven in high risk human papillomavirus infections, in cervical dysplasia and in various cervical carcinomas , . The results were clear-cut: the Santa-Cruz (sc-1661), Proteintech and Sigma antibodies all detected recombinant p16INK4A on Western blots and yielded robust immunolabelling in cervical carcinoma tissue sections, but, no specific p16INK4A immunolabelling was observed in the cornea, drainage angle, retina or optic nerve of human or rat tissue sections. These data correlate with the real-time PCR results and suggest that p16INK4A is not expressed to any significant degree in normal human or rat ocular tissues. The results also concur with previous studies that have investigated p16INK4A expression in retinoma  and retinoblastoma . In both of these studies, one of which featured Santa-Cruz antibody sc-1661, tumor cells were typically p16INK4A-positive, but adjacent, healthy retina was p16INK4A-negative. In contrast, clone 2D9A12 gave unsatisfactory results when used for Western blotting, less reliably demarcated p16INK4A overexpression in abnormal cervical cells, and, additionally elicited robust nuclear labelling of numerous cells in surrounding healthy cervical tissue in an analagous manner to that observed in ocular tissue sections. Our study raises serious questions about the specificity of Abnova clone 2D9A12. We might speculate that this antibody cross-reacts with p18INK4C or p19INK4D, which share significant homology with p16INK4A and are abundantly expressed in normal adult tissues , but further investigation would be needed to explore this possibility.
Human p14ARF (and the rodent equivalent, p19ARF) is derived from an alternative reading frame of the p16INK4A gene sequence , . Originally thought just to be a tumour-suppressor protein being co-expressed and therefore functioning in the same manner as p16INK4A, it was surprising to delineate that p14ARF had its own distinct but complementary role in the control of cell cycle entry . It is thought that this protein binds to Mdm2, which functions to ubiquitinylate the key cellular tumour-suppressor protein, p53, and therefore mark it for degradation by the proteasome . When p14ARF is expressed, usually under conditions of cellular stress, it sequesters Mdm2, allowing p53 levels to rise and activate the latter protein’s functions as a regulator of DNA damage repair, an abrogator of the cell cycle and a determinant in the instigation of cellular apoptosis . P14ARF therefore has a key role to play in the cellular response to stress and is therefore usually found, upon expression, within the nucleus.
When studying p14ARF in human cancerous cervical tissue sections, this protein was localized to nuclear inclusions in epithelial cells by two distinct antibodies (CST and Sigma) in agreement with the known subcellular localization of this protein . When applied to human ocular sections, however, no such labeling was seen in any cells and so we conclude that there was either no p14ARF expressed in the human eye or that, if present, its levels were so low as to be undetectable by our methods.
Initially studying p19ARF in rodent tissues, we found significant mRNA expression in the optic nerve relative to all other tissues examined. Subsequent analysis of tissues by labeling with two distinct antibodies (Upstate and Santa Cruz) revealed that, as expected, both labeled nuclei in immortalized mouse RGC-5 cells, with the Upstate antibody specifically recognizing nuclear inclusions which were reminiscent of nucleoli . Western blot data, however, was inconsistent: the Santa Cruz antibody could not recognize the recombinant protein, but could detect a 19 kD protein in rat optic nerve extracts, whereas the Upstate antibody correctly recognized the recombinant protein, but only revealed a 48 kD protein in brain and optic nerve. When rat ocular sections were examined, the Upstate antibody revealed strong immunolabelling in the fibres of the post-laminar optic nerve. We therefore believe that this antibody was actually recognizing a different axonal protein, an idea reinforced by the positive detection of a protein in only brain and optic nerve Western extracts. These findings thus rendered this antibody as inappropriate for further study in our studies. Alongside these data, the Santa Cruz antibody could detect no signal in any ocular cell-type or region and so no conclusion could be drawn as to its eligibility for further use. The only definitive conclusion that could be drawn from the p19ARF studies, therefore, was from the mRNA analyses, which was that expression within the normal retina is negligible but within the optic nerve measurably higher.
Like P16INK4A, p15INK4B is a member of the INK4 family of tumour-suppressor proteins and therefore also functions as a CDK4/6 inhibitor . As with other INK4 proteins, interaction with the target CDK prevents binding of cyclin D and this in turn blocks activation of G1/S-phase transition, holding the cell in a pre-divided state . Despite the similarities in the known binding properties of the INK4 group members, the specific functions of p15INK4B and the reasons why two structurally and functionally similar proteins are expressed from a single gene locus remain unknown. Furthermore, specific functions of p15INK4B are relatively enigmatic compared with those of p16INK4A. It is now believed, however, that p15INK4B acts generally as a cellular back-up for p16INK4A in the case of loss-of-function of the latter . P15INK4B has now been linked to the mechanism of TGFβ-induced cell cycle arrest . This could be of relevance to glaucoma since this latter growth factor is thought to play a role in the pathogenesis of optic nerve head damage in this disease .
Relatively little is known about the expression patterns and roles of p15INK4B in healthy mammals, but studies have shown it to be more widely distributed than p16INK4A , , . Our qPCR results support this generalisation: the levels of p15INK4B mRNA in the rat retina and brain were broadly similar with, as expected , a somewhat greater amount found in the liver. In all three tissues, the p15INK4B transcript was at a higher level than that of p16INK4A. Interestingly, our results also showed that, as was the case for p19ARF, there is a considerably greater expression of p15INK4B mRNA in the optic nerve than in the retina, although there was no significant difference in protein levels in these tissues. Delineation of p15INK4B protein expression in ocular tissues is more problematic than for p16INK4A, p19ARF and MTAP, since, to our knowledge, there is no definitive positive control tissue that can be utilised and no antibody clone that has been well characterized. P15INK4B protein expression has been documented using numerous different antibodies and the protein has been shown to be localised varyingly in the nucleus and cytoplasm. The situation is further complicated by the fact that FASTA sequence comparison of the human p15INK4B and p16INK4A proteins reveals 89.5% similarity, although importantly the N-termini of each protein retain little identity.
Of the four commercially available antibodies tested in the current study, two provided unsatisfactory results: (1) the Abcam p15INK4B polyclonal antibody recognised recombinant p16INK4A with equal potency to p15INK4B. This non-specific interaction obviously renders it unsuitable for further use; (2) the Santa-Cruz antibody (K-18), which has been used in numerous published studies, and, which was raised against a peptide mapping near the N-terminus engendering confidence in its specificity, provided us with expected labelling patterns in abnormal cervix and normal skin tissue sections. Unexpectedly, however, this antibody cross-reacted with an abundant 35kD protein in the retina that appears to be produced by photoreceptor outer segments. The two other antibodies used: a polyclonal antibody (CST) raised against a peptide mapping near the N-terminus and a monoclonal antibody (Neomarkers; clone 15P06) raised against full length p15INK4B, provided similar patterns of immunolabelling in ocular sections, namely a nuclear association with cells of the corneal epithelium, trabecular meshwork, optic nerve and retina, the latter of which appeared to be restricted to inner retinal neurons. Confidence in the validity of these results is strengthened by the accompanying satisfactory Western blotting results, pre-adsorption testing and labelling patterns in putative positive control tissues.
In conclusion, our results indicate that gene products of the 9p21 locus have defined and restricted patterns of expression in normal human and rodent ocular tissues. MTAP and p15INK4B (CDKN2B) are relatively widely expressed, while p16INK4A (CDKN2A) and p19ARF are essentially undetectable with the tools we have used in healthy ocular tissues. The information provided in this study provide a basis for exploring how expression of these gene products may alter in glaucoma and other ocular diseases.
Evaluation of MTAP antibodies by Western immunoblotting. (A) Evaluation of three MTAP antibodies (Cell Signaling Technology, CST; Santa-Cruz, sc; ProteinTech, PT), by Western immunoblotting using GST-tagged, full length, recombinant, human MTAP protein (rMTAP). For each antibody tested, molecular weight markers were used to determine size of detected gel products (A; lane M). Lane 1, 100 ng rMTAP; Lane 2, 10 ng rMTAP; Lane 3, 1 ng rMTAP; Lane 4, 100 pg rMTAP. Single bands of the expected molecular weights (including GST-tag) are apparent for each of the antibodies. (B) Rat brain cortex (lane 1), liver (lane 2), optic nerve (lane 3) and retina (lane 4) samples probed for MTAP with the CST, sc and PT antibodies. Each antibody is able to detect a protein at the correct molecular mass for MTAP in the liver, optic nerve and retinal samples. Labelling for β-actin (housekeeping gene) and α-tubulin (neuronal tissue marker) are also shown.
Evaluation of MTAP antibodies in malignant pleural mesothelioma. In formalin-fixed, paraffin-embedded tissue sections, the MTAP antibody from Proteintech (PT Ab; A) robustly labelled inflammatory cells. In comparison, MTAP antibodies from Cell Signaling Technology (CST Ab; B) and Santa-Cruz (sc Ab; C) elicited weaker labelling of inflammatory cells (see arrows). Scale bar = 30 µm.
Evaluation of p16INK4A antibodies, and p16INK4A expression in rat tissues, by Western immunoblotting. (A) Evaluation of four p16INK4A antibodies, from ProteinTech (PT), Sigma, Santa-Cruz (sc) and Abnova, by Western blotting, using GST-tagged, full length, recombinant, human p16INK4A protein (rp16INK4A). For each antibody tested, molecular weight markers were used to determine size of detected gel products (A; lane M). Lane 1, 100 ng of rp16INK4A; Lane 2, 10 ng rp16INK4A. Single bands of the expected molecular weights (including GST-tag) are apparent for each of the tested antibodies except the Abnova one. (B) Rat brain cortex (lane 1), liver (lane 2), optic nerve (lane 3) and retina (lane 4) samples probed for p16INK4A protein with the PT, Sigma, sc and Abnova antibodies. None of the antibodies detect proteins at the correct molecular mass for p16INK4A in any rat tissue sample. Labelling for β-actin (house-keeping gene product) is also shown. (C) The Sigma and PT antibodies were further tested against retina (lanes 1–3) and optic nerve (lanes 4–6) samples obtained from three different rats. The presence of p16INK4A protein is not detectable in any sample.
Evaluation of antibodies directed against p16INK4A in cervical adenocarcinoma. In formalin-fixed, paraffin-embedded tissue sections, incubation with either the Santa-Cruz (sc; A), Proteintech (PT; B) or Sigma (C) antibodies identifies so-called ‘block’ or ‘diffuse’ immunolabelling of ductal tissue with a high signal-to-background, as compared to adjacent tissue (arrow). The staining intensity is greatest for the sc Ab and weakest for the Sigma antibody. The Abnova (D) antibody only inconsistently labels abnormal tissue and, additionally, produces nuclear labelling of adjacent tissue (red asterisk). Further examination of the Abnova antibody in cervical intraepithelial neoplasia reveals that the pattern of immunolabelling again differs from that obtained with the sc Ab (E) featuring weaker staining of the epithelium and robust nuclear localisation of numerous cells residing in the stromal tissue (F; red asterisk). Scale bar = 30 µm.
Representative images of p16INK4A immunolabelling in human ocular tissues. In formalin-fixed, paraffin-embedded human eyes, no positive labelling for p16INK4A is discernible in the corneal epithelium, trabecular meshwork (TM)/Schlemm’s canal (SC), or retina, irrespective of whether the Sigma (A–C) OR Proteintech (D–F) antibody is used. Scale bar: A, B, D, E, G, H = 15 µm; C, F, I = 30 µm. GCL, ganglion cell layer; INL, inner nuclear layer.
Representative images of p16INK4A immunolabelling in rat retina and optic nerve. In formalin-fixed, paraffin-embedded rat retina (A–C) and optic nerve (D–F), no unambiguous, positive labelling for p16INK4A is discernible either in retina or in the optic nerve using the Sigma (A, D) or Proteintech (B, E) antibodies. In contrast, the Abnova antibody robustly labels all cell nuclei within the eye, as highlighted in the presented images of retina (C) and optic nerve (F). Scale bar: A–D = 30 µm; E–H = 15 µm. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer.
Representative images of p14ARF immunolabelling using the antibody from CST. In formalin-fixed, paraffin-embedded sections of cervical intraepithelial neoplasia, p14ARF expression is identified within nuclear inclusions (A). In formalin-fixed, paraffin-embedded human eyes, no positive nuclear labelling for p14ARF is discernible in the corneal epithelium (B), trabecular meshwork (TM)/Schlemm’s canal (SC) (C), retina (D), unmyelinated optic nerve (E), or myelinated optic nerve (F). However, robust labelling of axons in the myelinated, but not unmyelinated, optic nerve is apparent. This labelling is likely non-specific. Scale bar = 15 µm.
Evaluation of P15INK4B antibodies in the rat. (A) Evaluation of four P15INK4B antibodies, from Cell Signaling Technology (CST), Neomarkers (Neo), Abcam and Santa-Cruz (sc), by Western blotting using GST-tagged, full length, recombinant human P15INK4B (rP15INK4B) and P16INK4A (rP16INK4A) proteins. M, molecular weight markers. Left-hand column, reactivity of antibodies to rP15INK4B to determine specificity; right-hand column, reactivity of antibodies to rP16INK4A in order to determine whether antisera bind non-specifically to related proteins. Left-hand column: lane 1, 100 ng of rP15INK4B; Lane 2, 10 ng rP15INK4B; Lane 3, 1 ng rP15INK4B P; Lane 4, 100 pg rP15INK4B. Single bands of the expected molecular weights (for protein incorporating GST-tag) are apparent for each of the antibodies, except sc. Right-hand column: lane 1, 100 ng of rP16INK4A; Lane 2, 10 ng rP16INK4A; Lane 3, 1 ng rP16INK4A; Lane 4, 100 pg rP16INK4A. Abcam and, to a minor degree, Neo antibodies show non-specific reactivity with rP16INK4A. (B) Rat brain cortex (lane 1), liver (lane 2), optic nerve (lane 3) and retina (lane 4) samples probed for rP15INK4B with CST, Neo, Abcam and sc antibodies. The CST antibody recognises a 15 kD protein in all tissue samples but the labeling for the other antibodies is disparate and variable. (C) Further testing of the sc antibody against different retina (lanes 1–3) and optic nerve (lanes 4–6) extracts reveals that the former antibody recognizes a distinct 35 kD protein in the retina with a labeling pattern which appears identical to that shown by the anti-rhodopsin antibody, Ret-P1. (D) Incubation of rat retina tissue sections with the sc antibody reveals immunoreactivity to be associated with photoreceptor outer segments (white arrow). This labelling pattern resembles that of RET-P1 labelling of rhodopsin (data not shown) and is unlikely to represent p15INK4B, which is typically localised to the nucleus of cells.
Evaluation of antibodies directed against p15INK4B in cervical intraepithelial neoplasia and skin. In formalin-fixed, paraffin-embedded tissue sections, incubation with either the CST (A) or Santa-Cruz (B) p15INK4B antibodies results in weak, diffuse immunolabelling of the cervical intraepithelial neoplastic lesion (red asterisk) and robust labelling of a subset of inflammatory cells in the underlying stroma (arrow). In contrast, incubation with the Abcam (C) p15INK4B antibody yields a pattern of labelling that more closely resembles that of p16INK4A (D), namely stronger staining of the CIN and negligible association with stromal components. In skin sections, the CST (E) and Santa-Cruz (F) antibodies labelled cutaneous squamous cells (arrows) Scale bar: A–D = 30 µm; E, F = 60 µm.
We are grateful to Sonja Klebe for providing human ocular sections. We also thank Mark Daymon and Teresa Mammone for their technical assistance.
Conceived and designed the experiments: JPMW GC SS DPD KPB RJC JEC. Performed the experiments: JPMW GC SS DPD. Analyzed the data: JPMW GC SS DPD KPB RJC JEC. Contributed reagents/materials/analysis tools: JPMW GC SS DPD KPB RJC JEC. Wrote the paper: JPMW GC. Revising, editing manuscript: JPMW GC SS DPD KPB RJC JEC.
- 1. Chidlow G, Wood JP, Casson RJ (2007) Pharmacological neuroprotection for glaucoma. Drugs 67∶725–759.
- 2. Mitchell P, Smith W, Attebo K, Healey PR (1996) Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology 103∶1661–1669.
- 3. Quigley HA, Broman AT (2006) The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 90∶262–267.
- 4. Monemi S, Spaeth G, DaSilva A, Popinchalk S, Ilitchev E, et al.. (2005) Identification of a novel adult-onset primary open-angle glaucoma (POAG) gene on 5q22.1. Hum Mol Genet 14∶725–733.
- 5. Thorleifsson G, Walters GB, Hewitt AW, Masson G, Helgason A, et al.. (2010) Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma. Nat Genet 42∶906–909.
- 6. Wiggs JL, Kang JH, Yaspan BL, Mirel DB, Laurie C, et al.. (2011) Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma in Caucasians from the USA. Hum Mol Genet 20∶4707–4713.
- 7. Burdon KP, Macgregor S, Hewitt AW, Sharma S, Chidlow G, et al.. (2011) Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMCO1 and CDKN2B-AS1. Nat Genet 43∶574–578.
- 8. Gibson J, Griffiths H, De Salvo G, Cole M, Jacob A, et al.. (2012) Genome-wide association study of primary open angle glaucoma risk and quantitative traits. Mol Vis 18∶1083–1092.
- 9. van Koolwijk LM, Ramdas WD, Ikram MK, Jansonius NM, Pasutto F, et al. (2012) Common genetic determinants of intraocular pressure and primary open-angle glaucoma. PLoS Genet 8: e1002611.
- 10. Sharma S, Burdon KP, Chidlow G, Klebe S, Crawford A, et al.. (2012) Association of genetic variants in the TMCO1 gene with clinical parameters related to glaucoma and characterization of the protein in the eye. Invest Ophthalmol Vis Sci 53∶4917–4925.
- 11. Burdon KP, Crawford A, Casson RJ, Hewitt AW, Landers J, et al.. (2012) Glaucoma Risk Alleles at CDKN2B-AS1 Are Associated with Lower Intraocular Pressure, Normal-Tension Glaucoma, and Advanced Glaucoma. Ophthalmology 119∶1539–1545.
- 12. Cao D, Jiao X, Liu X, Hennis A, Leske MC, et al. (2012) CDKN2B polymorphism is associated with primary open-angle glaucoma (POAG) in the Afro-Caribbean population of Barbados, West Indies. PLoS One 7: e39278.
- 13. Fan BJ, Wang DY, Pasquale LR, Haines JL, Wiggs JL (2011) Genetic variants associated with optic nerve vertical cup-to-disc ratio are risk factors for primary open angle glaucoma in a US Caucasian population. Invest Ophthalmol Vis Sci 52∶1788–1792.
- 14. Mabuchi F, Sakurada Y, Kashiwagi K, Yamagata Z, Iijima H, et al.. (2012) Association between Genetic Variants Associated with Vertical Cup-to-Disc Ratio and Phenotypic Features of Primary Open-Angle Glaucoma. Ophthalmology 119∶1819–1825.
- 15. Nakano M, Ikeda Y, Tokuda Y, Fuwa M, Omi N, et al. (2012) Common variants in CDKN2B-AS1 associated with optic-nerve vulnerability of glaucoma identified by genome-wide association studies in Japanese. PLoS One 7: e33389.
- 16. Osman W, Low SK, Takahashi A, Kubo M, Nakamura Y (2012) A genome-wide association study in the Japanese population confirms 9p21 and 14q23 as susceptibility loci for primary open angle glaucoma. Hum Mol Genet 21∶2836–2842.
- 17. Ramdas WD, van Koolwijk LM, Ikram MK, Jansonius NM, de Jong PT, et al. (2010) A genome-wide association study of optic disc parameters. PLoS Genet 6: e1000978.
- 18. Ramdas WD, van Koolwijk LM, Lemij HG, Pasutto F, Cree AJ, et al.. (2011) Common genetic variants associated with open-angle glaucoma. Hum Mol Genet 20∶2464–2471.
- 19. Takamoto M, Kaburaki T, Mabuchi A, Araie M, Amano S, et al. (2012) Common variants on chromosome 9p21 are associated with normal tension glaucoma. PLoS One 7: e40107.
- 20. Wiggs JL, Yaspan BL, Hauser MA, Kang JH, Allingham RR, et al. (2012) Common variants at 9p21 and 8q22 are associated with increased susceptibility to optic nerve degeneration in glaucoma. PLoS Genet 8: e1002654.
- 21. Broadbent HM, Peden JF, Lorkowski S, Goel A, Ongen H, et al.. (2008) Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum Mol Genet 17∶806–814.
- 22. Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, et al.. (2007) A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316∶1491–1493.
- 23. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, et al.. (2007) A common allele on chromosome 9 associated with coronary heart disease. Science 316∶1488–1491.
- 24. Cunnington MS, Santibanez Koref M, Mayosi BM, Burn J, Keavney B (2010) Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes Correlate with ANRIL Expression. PLoS Genet 6: e1000899.
- 25. Pasmant E, Sabbagh A, Vidaud M, Bieche I (2011) ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J 25∶444–448.
- 26. Cunnington MS, Keavney B (2011) Genetic mechanisms mediating atherosclerosis susceptibility at the chromosome 9p21 locus. Curr Atheroscler Rep 13∶193–201.
- 27. Sato K, Nakagawa H, Tajima A, Yoshida K, Inoue I (2010) ANRIL is implicated in the regulation of nucleus and potential transcriptional target of E2F1. Oncol Rep 24∶701–707.
- 28. Christopher SA, Diegelman P, Porter CW, Kruger WD (2002) Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. Cancer Res 62∶6639–6644.
- 29. Hall M, Bates S, Peters G (1995) Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 11∶1581–1588.
- 30. Chidlow G, Daymon M, Wood JP, Casson RJ (2011) Localization of a wide-ranging panel of antigens in the rat retina by immunohistochemistry: comparison of Davidson’s solution and formalin as fixatives. J Histochem Cytochem 59∶884–898.
- 31. Chidlow G, Ebneter A, Wood JP, Casson RJ (2011) The optic nerve head is the site of axonal transport disruption, axonal cytoskeleton damage and putative axonal regeneration failure in a rat model of glaucoma. Acta Neuropathol 121∶737–751.
- 32. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72∶248–254.
- 33. Wood JP, Chidlow G, Graham M, Osborne NN (2005) Energy substrate requirements for survival of rat retinal cells in culture: the importance of glucose and monocarboxylates. J Neurochem 93∶686–697.
- 34. Van Bergen NJ, Wood JP, Chidlow G, Trounce IA, Casson RJ, et al.. (2009) Recharacterization of the RGC-5 retinal ganglion cell line. Invest Ophthalmol Vis Sci 50∶4267–4272.
- 35. Krishnamoorthy RR, Agarwal P, Prasanna G, Vopat K, Lambert W, et al.. (2001) Characterization of a transformed rat retinal ganglion cell line. Brain Res Mol Brain Res 86∶1–12.
- 36. Wood JP, Chidlow G, Tran T, Crowston J, Casson RJ (2010) A Comparison of Differentiation Protocols for Rgc-5 Cells. Invest Ophthalmol Vis Sci 51∶3774–3783.
- 37. Zimling ZG, Jorgensen A, Santoni-Rugiu E (2012) The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas. Histopathology 60: E96–105.
- 38. Mulvany NJ, Allen DG, Wilson SM (2008) Diagnostic utility of p16INK4a: a reappraisal of its use in cervical biopsies. Pathology 40∶335–344.
- 39. Tsoumpou I, Arbyn M, Kyrgiou M, Wentzensen N, Koliopoulos G, et al.. (2009) p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 35∶210–220.
- 40. Sano T, Masuda N, Oyama T, Nakajima T (2002) Overexpression of p16 and p14ARF is associated with human papillomavirus infection in cervical squamous cell carcinoma and dysplasia. Pathol Int 52∶375–383.
- 41. Bulten J, van der Avoort IA, Melchers WJ, Massuger LF, Grefte JM, et al.. (2006) p14ARF and p16INK4A, two products of the same gene, are differently expressed in cervical intraepithelial neoplasia. Gynecol Oncol 101∶487–494.
- 42. Qi Y, Gregory MA, Li Z, Brousal JP, West K, et al.. (2004) p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 431∶712–717.
- 43. Awad MM, Sanders JA, Gruppuso PA (2000) A potential role for p15(Ink4b) and p57(Kip2) in liver development. FEBS Lett 483∶160–164.
- 44. Feng W, Xiao J, Zhang Z, Rosen DG, Brown RE, et al.. (2007) Senescence and apoptosis in carcinogenesis of cervical squamous carcinoma. Mod Pathol 20∶961–966.
- 45. Moad AI, Lan TM, Kaur G, Hashim H, Mabruk MJ (2009) Immunohistochemical determination of the P15 protein expression in cutaneous squamous cell carcinoma. J Cutan Pathol 36∶183–189.
- 46. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, et al.. (2007) A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316∶1341–1345.
- 47. Rhodes KJ, Trimmer JS (2006) Antibodies as valuable neuroscience research tools versus reagents of mass distraction. J Neurosci 26∶8017–8020.
- 48. Fritschy JM (2008) Is my antibody-staining specific? How to deal with pitfalls of immunohistochemistry. Eur J Neurosci 28∶2365–2370.
- 49. Saper CB (2005) An open letter to our readers on the use of antibodies. J Comp Neurol 493∶477–478.
- 50. Burry RW (2011) Controls for immunocytochemistry: an update. J Histochem Cytochem 59∶6–12.
- 51. Williams-Ashman HG, Seidenfeld J, Galletti P (1982) Trends in the biochemical pharmacology of 5′-deoxy-5′-methylthioadenosine. Biochem Pharmacol 31∶277–288.
- 52. Garbers DL (1978) Demonstration of 5′-methylthioadenosine phosphorylase activity in various rat tissues. Biochimica et Biophysica Acta 523∶82–93.
- 53. Huang HY, Li SH, Yu SC, Chou FF, Tzeng CC, et al.. (2009) Homozygous deletion of MTAP gene as a poor prognosticator in gastrointestinal stromal tumors. Clin Cancer Res 15∶6963–6972.
- 54. Kim J, Kim MA, Min SY, Jee CD, Lee HE, et al.. (2011) Downregulation of methylthioadenosin phosphorylase by homozygous deletion in gastric carcinoma. Genes Chromosomes Cancer 50∶421–433.
- 55. Sommer J, Itani DM, Homlar KC, Keedy VL, Halpern JL, et al.. (2010) Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma. J Pathol 220∶608–617.
- 56. Romagosa C, Simonetti S, Lopez-Vicente L, Mazo A, Lleonart ME, et al.. (2011) p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene 30∶2087–2097.
- 57. Liggett WH Jr, Sidransky D (1998) Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16∶1197–1206.
- 58. Robertson KD, Jones PA (1999) Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus. Oncogene 18∶3810–3820.
- 59. Zindy F, Quelle DE, Roussel MF, Sherr CJ (1997) Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15∶203–211.
- 60. Quelle DE, Ashmun RA, Hannon GJ, Rehberger PA, Trono D, et al.. (1995) Cloning and characterization of murine p16INK4a and p15INK4b genes. Oncogene 11∶635–645.
- 61. Watanabe G, Pena P, Shambaugh GE 3rd, Haines GK 3rd, Pestell RG (1998) Regulation of cyclin dependent kinase inhibitor proteins during neonatal cerebella development. Brain Res Dev Brain Res 108∶77–87.
- 62. Dimaras H, Khetan V, Halliday W, Orlic M, Prigoda NL, et al.. (2008) Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma. Hum Mol Genet 17∶1363–1372.
- 63. Indovina P, Acquaviva A, De Falco G, Rizzo V, Onnis A, et al.. (2010) Downregulation and aberrant promoter methylation of p16INK4A: a possible novel heritable susceptibility marker to retinoblastoma. J Cell Physiol 223∶143–150.
- 64. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, et al.. (1995) A novel p16INK4A transcript. Cancer Res 55∶2995–2997.
- 65. Quelle DE, Zindy F, Ashmun RA, Sherr CJ (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83∶993–1000.
- 66. Bates S, Phillips AC, Clark PA, Stott F, Peters G, et al.. (1998) p14ARF links the tumour suppressors RB and p53. Nature 395∶124–125.
- 67. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, et al.. (1998) The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17∶5001–5014.
- 68. Sandhu C, Garbe J, Bhattacharya N, Daksis J, Pan CH, et al.. (1997) Transforming growth factor beta stabilizes p15INK4B protein, increases p15INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells. Mol Cell Biol 17∶2458–2467.
- 69. Krimpenfort P, Ijpenberg A, Song JY, van der Valk M, Nawijn M, et al.. (2007) p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature 448∶943–946.
- 70. Fuchshofer R, Tamm ER (2012) The role of TGF-beta in the pathogenesis of primary open-angle glaucoma. Cell Tissue Res 347∶279–290.
- 71. Legrier ME, Ducray A, Propper A, Kastner A (2001) Region-specific expression of cell cycle inhibitors in the adult brain. Neuroreport 12∶3127–3131.